Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Safety Profile of Vancomycin in Outpatient Parenteral Antimicrobial Therapy Services: A Systematic Review.

Antibiotics (Basel, Switzerland)·2026
Same author

The Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Infections in Patients With Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Sex differences in the diagnosis, management and outcomes of patients with infective endocarditis.

Open heart·2026
Same author

Correction: Global mapping of sexually transmitted Chlamydia trachomatis disease: a systematic review and meta-analysis.

BMC infectious diseases·2026
Same author

Being friendly to the skin microbiome: Experimental assessment.

Frontiers in microbiomes·2026
Same author

Point of care antimicrobial susceptibility testing.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026

Related Experiment Video

Updated: May 29, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

Immunotherapeutic approaches against Staphylococcus aureus.

Nelianne J Verkaik1, Willem J B van Wamel, Alex van Belkum

  • 1Erasmus Medical Center, Department of Medical Microbiology & Infectious Diseases's, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. n.j.verkaik@erasmusmc.nl

Immunotherapy
|September 15, 2011
PubMed
Summary

Developing vaccines against Staphylococcus aureus, including MRSA, is crucial due to rising antibiotic resistance. While animal studies show promise, human trials for antistaphylococcal vaccines have not yet succeeded.

More Related Videos

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Related Experiment Videos

Last Updated: May 29, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Microbiology

Background:

  • Staphylococcus aureus causes severe infections like bacteremia and endocarditis.
  • Antibiotic resistance, particularly Methicillin-resistant S. aureus (MRSA), necessitates alternative interventions.
  • Current treatment limitations highlight the urgent need for effective antistaphylococcal vaccines.

Purpose of the Study:

  • To review immunotherapeutic strategies against Staphylococcus aureus.
  • To evaluate the efficacy of antistaphylococcal vaccines in preclinical and clinical settings.
  • To discuss the feasibility of developing successful human Staphylococcus aureus vaccines.

Main Methods:

  • Analysis of published data from animal models of Staphylococcus aureus infection.
  • Review of human clinical trial results for antistaphylococcal vaccines.
  • Assessment of immunotherapeutic targets including surface components, toxins, and polysaccharides.

Main Results:

  • Passive immunization in animal models using antibodies against S. aureus components confers protection.
  • Human immunization studies have yielded less promising results to date.
  • No antistaphylococcal vaccine has successfully completed clinical trials.

Conclusions:

  • Despite promising preclinical data, translating vaccine efficacy to humans remains a significant challenge.
  • Further research is needed to overcome barriers in developing effective human antistaphylococcal vaccines.
  • The feasibility of successful human immunization against S. aureus requires innovative approaches.